For over 30 years, Genzyme is playing a pioneering role in the development of therapies for so-called "orphan diseases". Recently, we have started to focus on MS, having already recorded two treatments for this indication.
Genzyme's portfolio includes innovative therapies, which are made available in countries around the world for patients. These therapies represent significant steps in drug development. The research from Genzyme is focused on the development and making available of medicaments for patients who are not yet, or not sufficiently, treated.
With the focus on rare diseases and multiple sclerosis, Genzyme wants to make a positive difference in the lives of these patients and their families. www.genzyme.nl